Retatrutide Muscle Loss: First DXA Scan Data Revealed

The first body composition scan data on retatrutide has now been published in The Lancet Diabetes and Endocrinology, and for anyone currently using the drug, the findings are worth understanding carefully because the numbers reveal something that simple scale readings never could.

The study was a substudy of a phase 2 randomized controlled trial, and it enrolled 103 people living with type 2 diabetes who underwent DXA scanning at baseline and again at 36 weeks. DXA, which stands for dual-energy X-ray absorptiometry, is considered the gold standard method for distinguishing fat mass from lean mass in the body, so the data carries real weight compared to estimates derived from body weight alone.

At the highest dose tested, 12 milligrams, total fat mass fell by 23 percent over the 36-week period, and visceral fat, the metabolically dangerous fat that accumulates around the organs in the abdominal cavity, dropped by 31 percent. These are meaningful reductions, and visceral fat in particular is strongly associated with insulin resistance, cardiovascular risk, and systemic inflammation, so a 31 percent reduction there is clinically significant.

When researchers broke down where the total weight loss was actually coming from, they found that roughly 75 to 80 percent of it was fat mass, and the remaining 20 to 25 percent was lean mass. On the surface, that ratio looks acceptable and even reassuring, and it holds up reasonably well when compared to tirzepatide, which produces a similar split of approximately 75 percent fat loss. Semaglutide actually performs worse on this metric, with some data suggesting that around 40 percent of weight lost on that drug comes from lean tissue rather than fat.

So by the ratio alone, retatrutide looks competitive with the best available options, and it outperforms the most widely prescribed GLP-1 drug in terms of preserving lean mass as a share of total weight lost. But this is precisely where the conversation has to go further than the headline numbers, because the ratio only tells part of the story.

The more important variable is the absolute amount of weight being lost, and retatrutide produces more total weight loss than any other obesity drug currently available or in late-stage development. When someone loses 50 pounds on the 12 milligram dose, that 20 to 25 percent lean mass figure translates into roughly 10 to 15 pounds of muscle and other lean tissue gone from the body. That is a substantial amount regardless of how tidy the percentage looks in a table, and it has real consequences for metabolism, strength, physical function, and long-term weight maintenance.

This finding also challenges one of the central theoretical arguments made in favor of retatrutide over other drugs in its class. Retatrutide is a triple receptor agonist, meaning it activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor simultaneously, and the glucagon component was expected to be a key differentiator in how the drug affected body composition. The reasoning was that glucagon signaling shifts energy expenditure toward fat oxidation, essentially encouraging the body to burn stored fat preferentially while sparing lean tissue.

The DXA data does not support that theory, at least not in a way that produces a meaningfully better lean mass ratio than drugs without a glucagon receptor. The proportion of lean mass lost is similar to what has been observed with tirzepatide, which does not act on the glucagon receptor at all, and so the idea that the glucagon component would preferentially protect muscle during aggressive weight loss does not appear to be playing out in human trial data the way the mechanistic logic suggested it would.

What this means practically is that the drug itself is not doing the work of preserving muscle, and expecting it to do so because of its receptor profile would be a mistake. The glucagon receptor may still be contributing to the degree of fat loss and the improvements in visceral adiposity, but it does not appear to be fundamentally changing the lean mass equation in a way that allows someone to skip the behavioral inputs that muscle preservation actually requires.

Those inputs are resistance training and adequate protein intake, and they are not optional additions for people who want to get the most out of retatrutide, they are necessary for avoiding an outcome where the drug does its job but leaves the person with significantly less muscle than they started with. Resistance training, meaning compound movement patterns performed with sufficient frequency and load, provides the mechanical stimulus that tells the body muscle is worth keeping even during a large caloric deficit.

Protein intake operates on a different but complementary pathway, because dietary protein supplies the amino acids needed for muscle protein synthesis, and during periods of rapid weight loss the body's demand for those amino acids increases. A commonly cited target in the context of body recomposition and weight loss is at least one gram of protein per pound of goal body weight per day, and that target becomes especially important when someone is losing weight as quickly as retatrutide allows.

The trial in question enrolled people with type 2 diabetes, and it is worth noting that body composition dynamics can differ across populations, so the exact numbers may shift somewhat in trials involving people without diabetes or with different baseline characteristics. But the directional finding, that a significant portion of weight lost on retatrutide is lean mass, is unlikely to disappear in other populations because the underlying physiology of caloric deficit and muscle catabolism does not change dramatically based on diabetes status alone.

The broader takeaway from this data is that retatrutide is an extraordinarily powerful tool for reducing fat mass and visceral fat in particular, and it does so more aggressively than anything else currently available. But power is not the same as precision, and the drug does not selectively target fat in a way that protects muscle without deliberate effort from the person using it. Understanding this distinction early, before significant lean mass has been lost, is what allows someone to use the drug in a way that produces the best possible outcome rather than simply a lower number on the scale.

---

References

1. Gusenbauer M, Haddaway NR. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. Res Synth Methods. 2020. Source
2. Lindsey WT, Olin BR. PubMed searches: overview and strategies for clinicians. Nutr Clin Pract. 2013. Source
3. Pirani C, Camilleri J. Effectiveness of root canal filling materials and techniques for treatment of apical periodontitis: A systematic review. Int Endod J. 2023. Source
4. Coskun T, Wu Q, Schloot NC et al.. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. Source
5. Wang X, Wang X, Zhuang H et al.. A GLP-1 receptor agonist semaglutide attenuates cardiac microvascular injury in HFD/STZ-induced diabetic mice. Eur J Pharmacol. 2026. Source
6. Bonafede M, Rao A, Tchang BG. Overview of Novel Mechanisms in Obesity Pharmacotherapy and Implications for Cardiovascular Disease: A Narrative Review. Curr Atheroscler Rep. 2026. Source
7. Packer M. Evolutionary History of the Comorbidity-Driven Coronary Microvascular Endothelial Inflammation Hypothesis and Its Metamorphosis to the Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction. JACC Heart Fail. 2026. Source
8. Kadowaki T, Isendahl J, Khalid U et al.. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population STEP 6: a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022. Source
9. Gastaldelli A, Cusi K, Fernández Landó L et al.. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes SURPASS-3 MRI: a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022. Source
10. Bhandarkar A, Bhat S, Kapoor N. Effect of GLP-1 receptor agonists on body composition. Curr Opin Endocrinol Diabetes Obes. 2025. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness